Pipeline

Allist will strive to take its advantages in new drug discovery, increase R&D inputs, and intensify its efforts in accelerating exploring targeted drugs for cancer treatment.Meanwhile, Allist is working to expand its product pipeline in multiple ways including joint development and external introduction.

Furmonertinib
(Core product)

  • Approved
Second-line therapy for Non-small Cell Lung Cancer (NSCLC):EGFR T790M mutation-positive, locally advanced or metastatic NSCLC
  • APPROVED
First-line therapy for Non-small Cell Lung Cancer (NSCLC):EGFR mutation-positive, locally advanced or metastatic NSCLC
  • Phase III enrollment
Postoperative adjuvant therapy of NSCLC:Postoperative adjuvant therapy for patients with EGFR mutation-positive NSCLC at phase 1I-IIIa
  • Phase Ib enrollment
Second-line therapy for NSCLC:Applicable to advanced NSCLC with EGFR ex20ins mutation
  • Phase Ib enrollment
First-line therapy for NSCLC:Applicable to advanced NSCLC with EGFR ex20ins mutation

RETinhibitor

  • Preclinical study
NSCLC

KRAS G12C
inhibitor

  • Preclinical study
NSCLC, colorectal cancer, pancreatic cancer

KRAS G12D
inhibitor

  • Preclinical study
NSCLC, colorectal cancer, pancreatic cancer

SOS1
inhibitor

  • Preclinical study
NSCLC, colorectal cancer, pancreatic cancer

4th-generationEGFR
inhibitor

  • Preclinical study
NSCLC with C797S drug-resistant mutation after treatment with 3rd-generation EGFR inhibitor

Treatment of Malignant Tumor

Manufacturing
  • 73,337
    Square meter
  • 240
    Million RMB
    (registered capital)

As an innovative pharmaceutical industrialization base invested by Shanghai Allist Pharmaceuticals, Jiangsu Allist Pharmaceuticals Co.,LTD was founded in Sept 2009 with a  registered capital of 240 million RMB.Jiangsu Allist is located in No.666 Huashi Road, Qidong Economic Development Zone, Jiangsu Province, covering a total area of 73,337 square meter, 90Km away from Shanghai Pudong Airport, with convenient transportation and beautiful environment.

Scope of production license: Tablets (including antitumor drugs) and hard capsules (including antitumor drugs)